Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02969200|
Recruitment Status : Completed
First Posted : November 21, 2016
Last Update Posted : October 16, 2018
|Condition or disease||Intervention/treatment|
|Fabry Disease||Drug: Enzyme replacement therapy|
Nephropathy is common in Fabry disease (FD). Renal function decline is often the first sign of major organ involvement, sometimes progressing to end-stage renal failure. Available studies of renal function during enzyme replacement therapy have shown inconsistent results, and are based on different composition of patient materials and follow-up time.
Most investigations have used estimated glomerular filtration rate (eGFR) for evaluating renal function. GFR is an important indicator of renal function. eGFR based on a serum creatinine measurement is most commonly used in FD. However, this method has been shown to be unreliable, as serum creatinine levels are influenced by other factors than renal function such as ethnic group, muscle mass, age, hydration and diet. Performance of eGFR in detecting minor changes in renal function is poor. A 10 year old review on renal function evaluation in patients with FD recommended the use of GFR based on an exogenous marker, e.g. Cr-EDTA. Nevertheless, only few studies have used mGFR for evaluation of renal function and to our knowledge, the present study is the first to describe the rate of renal function decline with consecutive mGFR values in a nationwide population of patients with FD.
Renal function declines with age in renal healthy individuals. To our knowledge, the present study is the first to age-standardize renal function in patients with FD to adjust for age-dependent renal deterioration.
|Study Type :||Observational|
|Actual Enrollment :||52 participants|
|Official Title:||Fabry Disease: Renal Function During Long-term Enzyme Replacement Therapy Evaluated by Gold Standard GFR 51Cr-EDTA Clearance|
|Study Start Date :||April 2015|
|Actual Primary Completion Date :||September 2016|
|Actual Study Completion Date :||December 9, 2016|
- Drug: Enzyme replacement therapy
All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase betaOther Names:
- Fabrazyme (agalsidase beta)
- Replagal (agalsidase alfa)
- measured glomerular filtration rate [ Time Frame: Assessed every 6-12 months; from baseline and up to 15 years ]GFR was measured at least once a year by the one sample 51Cr-ethylenendiaminetetra acetic acid (EDTA) clearance technique using two (for duplicate determination) plasma samples 200 min after the injection of 4 (3.8-4.2) MBq 51Cr-EDTA. In children (< 15y) the injected 51Cr-activity was 3 MBq, and the blood-samples were collected 120 min after radiotracer injection. (< 5y: 2 MBq).
- urinary protein excretion [ Time Frame: Assessed every 6-12 months; from baseline and up to 15 years ]Repeated twenty-four hour urine samples were collected by patients at home, the last 24 hours before coming to the hospital. These samples were analysed for albumin, creatinine and protein. Furthermore spot urine samples were applied and analysed for albumin, creatinine and protein. Albumin-creatinine-ratio was calculated and abnormal values were defined as > 30 mg/g. Urine protein- and albumin values below detection limit (< 0.04 g/L and < 3 mg/L, respectively) were converted to zero for statistical analyses.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02969200
|National University Hospital, Department of Medical Endocrinology|
|Copenhagen, Denmark, DK-2100|
|Principal Investigator:||Ulla V Feldt-Rasmussen, MD, DMSc||Department of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet|